Canada Markets open in 3 hrs 37 mins

SeqLL Inc. (SQL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0700-0.6500 (-17.47%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.7200
Open3.7000
Bid3.1000 x 1000
Ask3.1600 x 800
Day's Range3.0400 - 3.7300
52 Week Range2.4000 - 5.8000
Volume1,208,443
Avg. Volume579,419
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SeqLL Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering

    WOBURN, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the closing of the sale of an additional 189,000 shares of common stock at the initial public offering price of $4.24 per share, pursuant to the partial exercise of the underwriters’

  • GlobeNewswire

    SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery Disease

    GW-Led Research uses SeqLL’s tSMS® platform to identify novel signature for detection of coronary artery diseaseWOBURN, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new blood-based RNA Sequencing method to d

  • GlobeNewswire

    SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform

    Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc. Funding for the research and method development provided by the National Institutes of Health (NIH) WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the pe